Login to Your Account

Creating Orphan Drugs Leader in Europe

Biovitrum Will Pay up to $533M for Swedish Orphan

By Cormac Sheridan

Wednesday, November 11, 2009
Biovitrum AB has taken a significant step in its goal to become a fully integrated, specialty pharmaceutical firm focused on niche indications, with an SEK3.656 billion (US$533.1 million) cash-and-shares acquisition of Swedish Orphan International AB. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription